Conflicted FDA Panel Supports UCB’s Arthritis sBLA, But Not AbbVie’s

An FDA advisory panel tasked with clearing up clinical trial uncertainty surrounding a pair of sBLAs for two TNF-blockers may have sowed further confusion Tuesday. The agency’s Arthritis Advisory Committee lodged conflicting votes on AbbVie’s Humira and UCB’s Cimzia, proposed for expanded indications in arthritis, citing concerns with subpopulations in both cases.
Drug Industry Daily